NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires con...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Stolichnaya Izdatelskaya Kompaniya
2015-09-01
|
Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
Subjects: | |
Online Access: | https://www.rpcardio.com/jour/article/view/193 |
id |
doaj-ef1ad42a0e174de288e3ca64e74cc1fa |
---|---|
record_format |
Article |
spelling |
doaj-ef1ad42a0e174de288e3ca64e74cc1fa2021-09-03T13:15:13ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532015-09-0110444444710.20996/1819-6446-2014-10-4-444-447193NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETYD. A. Napalkov0A. A. Sokolova1I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityComparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires consideration of special clinical situations that predispose to an increased risk of bleeding.https://www.rpcardio.com/jour/article/view/193anticoagulantsatrial fibrillationprevention of thromboembolismwarfarindabigatranrivaroxabanapixaban |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
D. A. Napalkov A. A. Sokolova |
spellingShingle |
D. A. Napalkov A. A. Sokolova NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Racionalʹnaâ Farmakoterapiâ v Kardiologii anticoagulants atrial fibrillation prevention of thromboembolism warfarin dabigatran rivaroxaban apixaban |
author_facet |
D. A. Napalkov A. A. Sokolova |
author_sort |
D. A. Napalkov |
title |
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
title_short |
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
title_full |
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
title_fullStr |
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
title_full_unstemmed |
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY |
title_sort |
new oral anticoagulants: focus on the safety |
publisher |
Stolichnaya Izdatelskaya Kompaniya |
series |
Racionalʹnaâ Farmakoterapiâ v Kardiologii |
issn |
1819-6446 2225-3653 |
publishDate |
2015-09-01 |
description |
Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires consideration of special clinical situations that predispose to an increased risk of bleeding. |
topic |
anticoagulants atrial fibrillation prevention of thromboembolism warfarin dabigatran rivaroxaban apixaban |
url |
https://www.rpcardio.com/jour/article/view/193 |
work_keys_str_mv |
AT danapalkov neworalanticoagulantsfocusonthesafety AT aasokolova neworalanticoagulantsfocusonthesafety |
_version_ |
1717817123295723520 |